MS/Neuro Reps & DMs: Celgene and Novartis will offer you more $$$

[anonymous]

And job security too, which is something that Genentech CANNOT OFFER ANY OF YOU RIGHT NOW.

Who REALLY wants to be paid less and work more for MBOs?

 

[anonymous]

Already heard that one DM went to Celgene and many more DMs and CS's to leave. This is going to be fun to watch!

 

[anonymous]

Great news because Hematology Reps will replace most Ocrevus CS's anyway- good ridance

 

[anonymous]

And job security too, which is something that Genentech CANNOT OFFER ANY OF YOU RIGHT NOW.

Who REALLY wants to be paid less and work more for MBOs?

This sounds like a pathetic recruiter. Go back to your Novartis board

 

[anonymous]

I work for Novartis. We don’t want or need any Genentech people. We are already maxed out on slackers.

 

[anonymous]

I work for Novartis. We don’t want or need any Genentech people. We are already maxed out on slackers.

No problem. NOBODY wants to work for Novartis - scourge of the industry.

 

[anonymous]

No problem. NOBODY wants to work for Novartis - scourge of the industry.

You will want to work for Novartis or the like. Once you lose our Genentech job, which many of us are about to do.

Get your head out of the sand. It isn't the old Genentech that we once knew.

 

[anonymous]

No one is truly safe at Genentech and just because MS is doing well doesn’t mean you’re protected for the foreseeable future. Wake up folks, The lay-offs are happening all around you so get your resume updated and practice your interviewing skills for an outside role. Lose your entitlement attitude or a hiring manager with another company will smell you out during the phone screen.
Those who have left on their own terms and with their integrity intact are doing fine away from the cesspool culture that B Anderson fueled not long ago.

 

[anonymous]

No one is truly safe at Genentech and just because MS is doing well doesn’t mean you’re protected for the foreseeable future. Wake up folks, The lay-offs are happening all around you so get your resume updated and practice your interviewing skills for an outside role. Lose your entitlement attitude or a hiring manager with another company will smell you out during the phone screen.
Those who have left on their own terms and with their integrity intact are doing fine away from the cesspool culture that B Anderson fueled not long ago.

 

[anonymous]

I heard that DM's have to interview to keep their jobs. Is this true? Laughable if so. Most successful drug launch in Genentech and this is how you treat your people leaders??? If this is not scum, I don't know what is?
Mass exodus to come soon. Just watch.

 

[anonymous]

I heard that DM's have to interview to keep their jobs. Is this true? Laughable if so. Most successful drug launch in Genentech and this is how you treat your people leaders??? If this is not scum, I don't know what is?
Mass exodus to come soon. Just watch.

AH didn’t have to interview initially, think she will have to this time? AVB isn’t around to protect her....

 

[anonymous]

AH is as old as dirt- needs to retire

 

[anonymous]

No problem. NOBODY wants to work for Novartis - scourge of the industry.

That’s funny cause Novartis pays more, has a much better 401k match and is literally the leader in oncology, rheumatology and neuro. And soon gene therapy.

It’s about who pays the most, who your boss is and to some extent the product. Novartis checks 2 of the boxes right off the bat.

 

[anonymous]

That’s funny cause Novartis pays more, has a much better 401k match and is literally the leader in oncology, rheumatology and neuro. And soon gene therapy.

It’s about who pays the most, who your boss is and to some extent the product. Novartis checks 2 of the boxes right off the bat.

Wooooo Sounds inviting.

 

[anonymous]

The leader in oncology...really???

 

[anonymous]

Bahahahahahahahahaha- DMs have to interview to keep your jobs? Bahahahahahahahaha can I sign up to be on the interview panel?

 

[anonymous]

That’s funny cause Novartis pays more, has a much better 401k match and is literally the leader in oncology, rheumatology and neuro. And soon gene therapy.

It’s about who pays the most, who your boss is and to some extent the product. Novartis checks 2 of the boxes right off the bat.

What a laugh. Better back away from the Koolaid.

 

[anonymous]

Bahahahahahahahahaha- DMs have to interview to keep your jobs? Bahahahahahahahaha can I sign up to be on the interview panel?

So much for being on the most successful Genentech launch team ever. Losers. I can see that your leadership has complete faith in you - not

 

[anonymous]

The leader in oncology...really???

Novartis had some really big oncology drugs. And they do have the Cart-T drug. But leader? Although a good question- I wonder who our Dr.'s think is the true leader these days? Merck? BMS? Keytruda is huge.

 

[anonymous]

Top Selling Oncology Drugs 2018
Spoiler Alert: not much Genentech on this list once the big three fall off

10. Xtandi® (enzalutamide)
Astellas Pharma and Pfizer
Type of Drug: Androgen receptor inhibitor
2018 Sales: $3.624 billion (¥327.8 billion [$2.925 billion Astellas + $0.699 billion Pfizer)
2017 Sales: $3.116 billion (¥282.8 billion [$2.526 billion Astellas + $0.590 billion Pfizer)
% Change: 16.3%



9. Ibrance® (palbociclib)
Pfizer
Type of Drug: Kinase inhibitor
2018 Sales: $4.118 billion 1
2017 Sales: $3.126 billion 1
% Change: 31.7%



8. Neulasta/Peglasta (pegfilgrastim)
Amgen and Kyowa Hakko Kirin
Type of Drug: Leukocyte growth factor
2018 Sales: $4.684 billion ($4.475 billion Amgen + $0.209 billion [¥23.1 billion] Kyowa Hakko Kirin)
2017 Sales: $4.716 billion ($4.534 billion Amgen + $0.182 billion [¥20.1 billion] Kyowa Hakko Kirin)
% Change: -0.7%



7. Imbruvica® (ibrutinib)
Pharmacyclics (AbbVie) and Johnson & Johnson (J&J)
Type of Drug: Kinase inhibitor
2018 Sales: $6.205 billion ($3.590 billion Pharmacyclics [AbbVie] + $2.615 billion J&J)
2017 Sales: $4.466 billion ($2.573 billion Pharmacyclics [AbbVie] + $1.893 billion J&J)
% Change: 38.9%



6. Rituxan®/MabThera (rituximab)
Genentech (Roche) and Biogen 2
Type of Drug: CD20-directed cytolytic antibody
2018 Sales: $6.750 billion [CHF 6.752 billion] 2
2017 Sales: $7.298 billion [CHF 7.300 billion] 2
% Change: -7.5%



5. Avastin
Roche
Type of Drug: Vascular endothelial growth factor–directed antibody
2018 Sales: $6.822 billion (CHF 6.849 billion)
2017 Sales: $6.662 billion (CHF 6.688 billion)
% Change: 2.4%



4. Herceptin
Roche (Genentech)
Type of Drug: HER2/neu receptor antagonist
2018 Sales: $6.951 billion (CHF 6.982 billion)
2017 Sales: $6.983 billion (CHF 7.014 billion)
% Change: -0.5%



3. Keytruda
Merck & Co.
Type of Drug: Programmed death receptor-1 (PD-1)-blocking antibody
2018 Sales: $7.171 billion
2017 Sales: $3.809 billion
% Change: 88.3%



2. Opdivo
Bristol-Myers Squibb (BMS) and Ono Pharmaceutical
Type of Drug: Programmed death receptor-1 (PD-1) blocking antibody
2018 Sales: $7.570 billion ($6.735 billion BMS + $835 million [¥92.5 billion] Ono)
2017 Sales: $5.763 billion ($4.948 billion BMS + $815 million [¥90.2 billion] Ono)
% Change: 31.4%



1. Revlimid
Celgene
Type of Drug: Thalidomide analogue
2018 Sales: $9.685 billion
2017 Sales: $8.187 billion
% Change: 18.3%